RVL Pharmaceuticals plc
RVL Pharmaceuticals plc, headquartered in the United States, is a prominent player in the biopharmaceutical industry, specialising in innovative therapies for eye care. Founded in 2018, the company has quickly established itself as a leader in the development of unique ophthalmic products, notably its flagship treatment, Upneeq, which addresses acquired ptosis. With a focus on enhancing patient outcomes, RVL Pharmaceuticals is dedicated to advancing the field of ophthalmology through cutting-edge research and development. The company has achieved significant milestones, including successful product launches and strategic partnerships that bolster its market position. As RVL continues to expand its operational footprint, it remains committed to delivering high-quality, effective solutions that meet the evolving needs of healthcare professionals and patients alike.
DitchCarbon Score
How does RVL Pharmaceuticals plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
RVL Pharmaceuticals plc's score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
RVL Pharmaceuticals plc's reported carbon emissions
RVL Pharmaceuticals plc, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that RVL Pharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the pharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for RVL Pharmaceuticals to consider developing and implementing strategies to measure and reduce its carbon emissions in alignment with industry standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
RVL Pharmaceuticals plc is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
